Accelrys Adds Laboratory Information Management System to Software Suite - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelrys Adds Laboratory Information Management System to Software Suite


The Accelrys Process Management and Compliance Suite has been expanded with the addition of the Accelrys Laboratory Information Management System (LIMS), the company announced in a press release. This system uses a process-driven approach, which focuses on laboratory, quality-control, and manufacturing processes, in contrast to the sample-driven approach used by traditional LIMS. This process-driven approach enables organizations to achieve repeatability and consistency of procedures, automatically qualify operational changes, and maintain a lower total cost of ownership.

"Traditional systems deployed to support laboratory operations today lack the flexibility to manage the change inherent in the hand-off between departments that drive the scientific innovation cycle," said IDC Health Insights Research Director Alan Louie, PhD., in the press release. "By coming at LIMS from the process execution standpoint, companies like Accelrys are taking a more holistic approach to managing data. This approach is well suited for lab operations that are trying to drive standardization across changing environments while still maintaining process repeatability and regulatory compliance."

The Accelrys LIMS integrates with Accelrys Electronic Laboratory Notebook (ELN), Accelrys Laboratory Execution System (LES), Accelrys Electronic Batch Records (EBR), Accelrys Discoverant process management informatics, and the Accelrys Enterprise Platform (AEP) for data exchange to provide an end-to-end informatics system that makes data accessible across an organization.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here